Comparisons of the pharmacokinetics and tolerability of fixed-dose combinations of amlodipine besylate/losartan and amlodipine camsylate/losartan in healthy subjects: a randomized, open-label, single-dose, two-period, two-sequence crossover study

被引:9
作者
Choi, YoonJung [1 ]
Lee, SeungHwan [2 ]
Cho, Sang-Min [3 ]
Kang, Won-Ho [3 ]
Nam, Kyu-Yeol [4 ]
Jang, In-Jin [1 ]
Yu, Kyung-Sang [1 ]
机构
[1] Seoul Natl Univ, Coll Med, Dept Clin Pharmacol & Therapeut, Seoul, South Korea
[2] Seoul Natl Univ Hosp, Clin Trials Ctr, Seoul, South Korea
[3] Korea United Pharm Inc, Res Inst, Seoul, South Korea
[4] Korea United Pharm Inc, Global R&D, Seoul, South Korea
关键词
comparative pharmacokinetics; amlodipine; losartan; drug development; BLOOD-PRESSURE; DOUBLE-BLIND; CLINICAL PHARMACOKINETICS; ESSENTIAL-HYPERTENSION; CIRCADIAN VARIATION; RECEPTOR BLOCKERS; ANGIOTENSIN-II; PHASE-III; 8-WEEK; METABOLITES;
D O I
10.2147/DDDT.S113891
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Background: A fixed-dose combination (FDC) of amlodipine and losartan has been used to reduce blood pressure in patients whose hypertension is not sufficiently controlled with either drug alone. The aim of this study was to evaluate the pharmacokinetic (PK) characteristics and tolerability of an FDC of 6.94 mg amlodipine besylate (5 mg as amlodipine)/50 mg losartan potassium compared to an FDC of 5 mg amlodipine camsylate/50 mg losartan potassium in healthy subjects. Subjects and methods: A randomized, open-label, single-dose, two-period, two-sequence crossover study was conducted on 46 healthy male subjects. Blood concentrations were measured by liquid chromatography-tandem mass spectrometry. Blood samples were collected up to 144 hours post dose for each period. PK parameters were calculated in each treatment group using a noncompartmental method. The 90% confidence intervals (CIs) of the geometric mean ratios of the two treatments for the maximum plasma concentration (C-max) and the area under the concentration curve from time zero to the last quantifiable time point (AUC(0-t)) were estimated. Tolerability assessments were performed for all subjects who received the drug at least once. Results: The PK profiles of the two treatments were similar. For amlodipine, the geometric mean ratios (90% CIs) of amlodipine besylate to amlodipine camsylate for the Cmax and AUC(0-t) were 0.98 (0.94-1.01) and 0.97 (0.93-1.01), respectively. The corresponding values for losartan were 0.91 (0.81-1.02) and 1.05 (0.98-1.12), respectively. The incidence of adverse events was not significantly different between the two treatments, and both were well tolerated. Conclusion: An FDC of 6.94 mg amlodipine besylate (5 mg as amlodipine)/50 mg losartan potassium produced similar results to an FDC of 5 mg amlodipine camsylate/50 mg losartan potassium treatment with respect to the PK parameters of amlodipine and losartan based on C-max and AUC(0-t) values. The amlodipine besylate/losartan potassium combination was well tolerated by healthy male subjects.
引用
收藏
页码:3021 / 3028
页数:8
相关论文
共 34 条
[1]   High-dose monotherapy vs low-dose combination therapy of calcium channel blockers and angiotensin receptor blockers in mild to moderate hypertension [J].
Andreadis, EA ;
Tsourous, GI ;
Marakomichelakis, GE ;
Katsanou, PM ;
Fotia, ME ;
Vassilopoulos, CV ;
Diamantopoulos, EJ .
JOURNAL OF HUMAN HYPERTENSION, 2005, 19 (06) :491-496
[2]  
[Anonymous], 2011, HYPERT CLIN MAN PRI
[3]  
[Anonymous], 2010, GUID INV BIOEQ
[4]   Using Fixed-Dose Combination Therapies to Achieve Blood Pressure Goals [J].
Chrysant, Steven G. .
CLINICAL DRUG INVESTIGATION, 2008, 28 (11) :713-734
[5]  
Davison E, 1989, European patent, Patent No. [EP 0244944 B1, 0244944]
[6]   Compliance With the Treatment of Hypertension: The Potential of Combination Therapy [J].
Erdine, Serap .
JOURNAL OF CLINICAL HYPERTENSION, 2010, 12 (01) :40-46
[7]  
European Medicines Agency, QUEST ANSW POS SPEC
[8]  
FDA Guidance for Industry, 2003, BIOAV BIOEQ STUD OR
[9]   Indirect treatment comparison between fixed-dose-combinations of amlodipine/losartan and amlodipine/valsartan in blood pressure control [J].
Gould, A. Lawrence ;
Unniachan, S. ;
Wu, D. .
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2014, 68 (02) :163-172
[10]   Ambulatory Blood Pressure Monitoring in the Diagnosis and Management of Hypertension [J].
Grossman, Ehud .
DIABETES CARE, 2013, 36 :S307-S311